Search form



CL Mobile Menu

Diabetes Type 2

SGLT2 Inhibitor Q & A

Four questions for you to answer, four facts you need to know.


Diabetes Type 2

The renal protective effects seen with the SGLT2 inhibitor canogliflizin may be independent of glycemic control, suggest authors of a new post-hoc analysis.

A large Danish study compared community antibiotic use and hospital-treated infections between people with and without type 2 diabetes.

A Swedish study in twins has drawn criticism for limitations but the results reinforce the strong link between obesity and type 2 diabetes.

Brief slideshow summaries highlight Pokémon’s potential for diabetes prevention and other noteworthy study findings.

The good news is that a few diabetes drugs now show valid cardioprotective benefits; the bad news is the drugs are unaffordable for many.

Results of the intensive 12-week intervention included a significant drop in healthcare utilization, missed work days, and A1c levels.


Subscribe to Diabetes Type 2 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.